116 results on '"Thota, Prashanthi N."'
Search Results
2. Prediction of neoplastic progression in Barrett's esophagus using nanoscale nuclear architecture mapping: a pilot study.
3. How I Do It: ESD Versus EMR for EAC
4. Mo1273 QUALITATIVELY EVALUATING CHATGPT'S ACCURACY IN PROVIDING ANSWERS ON GASTROESOPHAGEAL REFLUX DISEASE RELATED QUESTIONS.
5. Mo1265 IMPACT OF GLP-1 AGONIST TREATMENT ON GERD OUTCOMES IN DIABETIC PATIENTS: INSIGHTS FROM A PROPENSITY-MATCHED STUDY IN THE UNITED STATES.
6. Su1254 EPIDEMIOLOGY AND CHARACTERISTICS OF BARRETT'S ESOPHAGUS IN PATIENTS WITH AND WITHOUT GERD: A LARGE US POPULATION STUDY.
7. Sa1267 ESOPHAGEAL LUMINAL DIAMETER IS ASSOCIATED WITH DYSPHAGIA IN EOSINOPHILIC ESOPHAGITIS: IMPLICATIONS FOR ENDOSCOPIC DILATION THERAPY.
8. 963 THE BREATH METABOLOME SIGNATURE IS LINKED WITH DIAGNOSIS OF EOSINOPHILIC ESOPHAGITIS: PILOT STUDY ASSESSING EXHALED VOLATILE ORGANIC COMPOUNDS.
9. 392 THE TISSUE SYSTEMS PATHOLOGY TEST ENABLES RISK-ALIGNED MANAGEMENT FOR PATIENTS WITH BARRETT'S ESOPHAGUS.
10. GERD: A practical approach.
11. Peroral endoscopic myotomy is highly effective for achalasia patients with recurrent symptoms after pneumatic dilatation
12. Trends and risk factors for 30-day readmissions in patients with acute cholangitis: analysis from the national readmission database
13. Quality of Colonoscopy: A Comparison Between Gastroenterologists and Nongastroenterologists
14. Obesity Does Not Impact Outcomes or Rates of Gastroesophageal Reflux After Peroral Endoscopic Myotomy in Achalasia
15. Clinical Outcomes Based on the Timing of Appearance of Visible Lesions in Barrett’s Esophagus During Endoscopic Eradication Therapy
16. Proposal of high-risk adenoma detection rate as an impactful, complementary quality indicator of colonoscopy
17. Current management of Barrett esophagus and esophageal adenocarcinoma.
18. Lower Annual Rate of Progression of Short-Segment vs Long-Segment Barrett's Esophagus to Esophageal Adenocarcinoma.
19. Reintervention After Heller Myotomy for Achalasia: Is It Inevitable?
20. Peroral Endoscopic Myotomy Is Safe and Highly Effective Treatment for Advanced Achalasia With Sigmoid Esophagus
21. Hospital Utilization in Patients With Gastric Cancer and Factors Affecting In-Hospital Mortality, Length of Stay, and Costs
22. Identification of a key role of widespread epigenetic drift in Barrett's esophagus and esophageal adenocarcinoma.
23. Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy.
24. Tu1271 A TISSUE SYSTEMS PATHOLOGY TEST ENABLES STANDARDIZED, RISK-ALIGNED MANAGEMENT OF PATIENTS WITH BARRETT'S ESOPHAGUS.
25. Sa1296 FACTORS ASSOCIATED WITH PERSISTENT ESOPHAGEAL SYMPTOMS IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS POST HISTOLOGICAL REMISSION.
26. 222 A TISSUE SYSTEMS PATHOLOGY TEST OUTPERFORMS STANDARD CLINICOPATHOLOGIC VARIABLES IN PREDICTING PROGRESSION IN PATIENTS WITH BARRETT'S ESOPHAGUS.
27. Peroral Endoscopic Myotomy Is Effective for Patients With Achalasia and Normal Lower-Esophageal Sphincter Relaxation Pressures.
28. Is Mass Screening for Barrett's Esophagus a Myth or Reality?
29. Outcomes Associated With Timing of ERCP in Acute Cholangitis Secondary to Choledocholithiasis
30. NANOSCALE NUCLEAR ARCHITECTURE MAPPING PREDICTS NEOPLASTIC PROGRESSION IN BARRETT'S ESOPHAGUS: A PROOF OF CONCEPT STUDY.
31. Markers of Vitamin D Exposure and Esophageal Cancer Risk: A Systematic Review and Meta-analysis.
32. Adenoma detection rate in high-risk patients differs from that in average-risk patients.
33. Achalasia: current therapeutic options
34. Racial Disparity in the Sex Distribution, the Prevalence, and the Incidence of Dysplasia in Barrett’s Esophagus
35. Efficacy of peroral endoscopic myotomy for the treatment of functional esophagogastric junction outflow obstruction
36. Post-ablation lymphocytic esophagitis in Barrett esophagus with high grade dysplasia or intramucosal carcinoma
37. Post-ablation lymphocytic esophagitis in Barrett esophagus with high grade dysplasia or intramucosal carcinoma
38. Polypectomy Rate: A Surrogate for Adenoma Detection Rate Varies by Colon Segment, Gender, and Endoscopist.
39. ID: 3522484 LONG-TERM OUTCOMES OF PER ORAL ENDOSCOPIC MYOTOMY VERSUS LAPAROSCOPIC HELLER MYOTOMY: A SYSTEMATIC REVIEW AND META-ANALYSIS.
40. Mo1161: ACCURACY OF A NON-ENDOSCOPIC ESOPHAGEAL SAMPLING DEVICE AND BIOMARKER PANEL FOR DETECTION OF BARRETT'S ESOPHAGUS (BE).
41. Tu1167a: DISTAL ESOPHAGEAL MICROBIOME AND MYCOBIOME IN BARRETT'S ESOPHAGUS (BE) & ESOPHAGEAL ADENOCARCINOMA (EAC).
42. 693: PATIENTS WITH ESOPHAGEAL ADENOCARCINOMA WITH PRIOR GERD SYMPTOMS ARE SIMILAR TO THOSE WITHOUT GERD: A PROSPECTIVE CROSS-SECTIONAL STUDY.
43. Q: Are there alternatives to surgery for Zenker diverticulum?
44. Wide-area transepithelial sampling for dysplasia detection in Barrett's esophagus: a systematic review and meta-analysis.
45. In reply.
46. Barrett’s Esophagus in Women: Demographic Features and Progression to High-Grade Dysplasia and Cancer.
47. Adenoma and Sessile Serrated Polyp Detection Rates
48. Management of nondysplastic Barrett’s esophagus: When to survey? When to ablate?
49. Correction to: Trends and risk factors for 30‑day readmissions in patients with acute cholangitis: analysis from the national readmission database
50. Su1181 IS ENDOSCOPIC ULTRASOUND (EUS) NECESSARY FOR PREDICTING THE NEED FOR NEOADJUVANT THERAPY IN ESOPHAGEAL ADENOCARCINOMA (EAC)?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.